Varro

Varro Life Sciences is an innovative diagnostics company building a rapid, non-invasive pathogen detection platform centered on its proprietary Micro Immunoelectrodes (MIEs). The technology uses nanobody-based electrochemical biosensors to identify pathogens in breath or air with high specificity, targeting applications in public health, agriculture, transportation, and built environments. Backed by a $42.5 million investment and led by a seasoned team with biotech and financial markets expertise, Varro is advancing its product portfolio and expanding its operations to commercialize its ultrafast, low-cost detection solutions.

Integrated real-time pathogen identification platform using Micro Immunoelectrodes (MIEs) – customizable electrochemical biosensors that utilize nanobodies for rapid, specific detection of pathogens in breath or air samples.

Varro competes in the rapid diagnostic space against companies like Cue Health and Lucira, and in environmental pathogen detection against firms like Thermo Fisher Scientific and startup peers. Its differentiation hinges on the combination of breath sampling, 60-second electrochemical detection using nanobodies, and a low-cost structure aimed at enabling widespread, frequent testing.